Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib and Defactinib with mFOLFIRINOX in Pancreatic Adenocarcinoma
NCT07824960Phase 2Not yet recruiting
- Sponsor
- University of Virginia
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 2 trial of avutometinib, defactinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Virginia. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07824960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07824960.